SCHEMBL2385648

SCHEMBL2385648

O=C(O)CC/C=C/c1ccnc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATG4B Q9Y4P1 2/20 0.52
KMT2A Q03164 6/20 0.50
MAPT P10636 5/20 0.50
ALDH1A1 P00352 5/20 0.50
MEN1 O00255 5/20 0.50
HPGD P15428 4/20 0.50
HTT P42858 2/20 0.50
LMNA P02545 1/20 0.50
CASP3 P42574 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
HSP90AA1 P07900 1/20 0.49
ATM Q13315 1/20 0.49
CYP1A2 P05177 4/20 0.49
MAPK1 P28482 3/20 0.49
KDM4E B2RXH2 3/20 0.49
CYP2C19 P33261 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385650 1.00 ATG4B (0.52) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL12251077 0.81 ATG4B (0.44) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL6851986 0.79 MAPT (0.58) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL3396868 0.79 MAPT (0.58) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL2385781 0.77 MAPT (0.62) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL2385787 0.77 MAPT (0.62) ATG4BKMT2AMAPTALDH1A1MEN1
Beta-Alanine SCHEMBL28052216 0.76 MAPT (0.59) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL10246109 0.75 MAPT (0.57) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL1677887 0.75 MAPT (0.57) ATG4BKMT2AMAPTALDH1A1MEN1
SCHEMBL1677889 0.75 MAPT (0.57) ATG4BKMT2AMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 ATG4B 1648/4885KMT2A 568/4885MAPT 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.